Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAiRegenerative MedicineCell TherapyGene Therapy

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1785958

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1785958

Cellular Starting Materials

PUBLISHED:
PAGES: 220 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Cellular Starting Materials Market to Reach US$5.0 Billion by 2030

The global market for Cellular Starting Materials estimated at US$1.5 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Cellular Starting Leukopaks, one of the segments analyzed in the report, is expected to record a 25.5% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Cellular Starting Cells & Tissues segment is estimated at 16.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$403.0 Million While China is Forecast to Grow at 20.5% CAGR

The Cellular Starting Materials market in the U.S. is estimated at US$403.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$760.8 Million by the year 2030 trailing a CAGR of 20.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 20.5% and 18.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.

Global Cellular Starting Materials Market - Key Trends & Drivers Summarized

How Are Cellular Starting Materials Revolutionizing Biotechnology?

Cellular starting materials serve as the foundation for a wide range of biopharmaceutical applications, including cell therapy, regenerative medicine, and vaccine development. These materials, which include stem cells, primary cells, and cell lines, are critical for advancing scientific research and producing innovative therapies for diseases such as cancer, autoimmune disorders, and neurodegenerative conditions. With the rapid expansion of precision medicine, the demand for high-quality and well-characterized cellular starting materials is increasing. Advancements in biotechnology and genetic engineering have further improved the scalability and reproducibility of cellular starting materials. Innovations in cell culture techniques, bioprocessing technologies, and cryopreservation methods are ensuring the stability and viability of these materials, making them more reliable for research and therapeutic applications. As the pharmaceutical and biotechnology sectors continue to evolve, cellular starting materials are becoming indispensable in the development of next-generation medical treatments.

Why Is the Demand for Cellular Starting Materials Increasing?

The rising prevalence of chronic and genetic diseases is driving the need for advanced cell-based therapies, fueling the demand for cellular starting materials. Researchers are leveraging these materials to develop personalized treatments that enhance patient outcomes by targeting specific genetic and molecular pathways. The growing focus on regenerative medicine, including stem cell therapies and tissue engineering, is further contributing to market expansion. Moreover, the increasing number of clinical trials in the field of cellular immunotherapy, gene therapy, and vaccine production is amplifying the demand for standardized and ethically sourced cellular starting materials. Regulatory agencies are emphasizing quality control and traceability in cellular material procurement, leading to advancements in sourcing, validation, and storage techniques. As cell-based research expands into new therapeutic areas, the need for reliable and scalable cellular starting materials will continue to grow.

Which Regions Are Leading the Cellular Starting Materials Market?

North America is currently the largest market for cellular starting materials, driven by strong investments in biotechnology, a well-established pharmaceutical industry, and extensive government support for biomedical research. The United States leads in cell-based therapy development, with numerous biotech firms and research institutions actively engaged in developing novel cell-based treatments. Europe follows closely, with countries like Germany, the UK, and France making significant advancements in cell therapy and regenerative medicine. The European Medicines Agency (EMA) has been actively involved in establishing regulatory frameworks for cell-based therapies, further strengthening market growth. Meanwhile, the Asia-Pacific region is experiencing rapid expansion due to increasing government initiatives, rising healthcare expenditures, and a growing number of clinical trials in Japan, China, and South Korea. These regions are expected to drive substantial market growth as cell-based research and therapy adoption increase.

What Are the Key Factors Driving Market Growth?

The growth in the Cellular Starting Materials market is driven by several factors, including advancements in stem cell research, increasing adoption of cell-based therapies, and the rising demand for regenerative medicine. The integration of artificial intelligence (AI) and automation in cell culture and quality control processes is improving efficiency and scalability, making cellular starting materials more accessible for research and therapeutic applications. Additionally, the expansion of biopharmaceutical manufacturing capabilities and the growing focus on precision medicine are propelling demand for high-quality cellular starting materials. The increasing number of strategic collaborations between research institutions, biotech firms, and pharmaceutical companies is further accelerating market growth. As cell-based treatments become more mainstream, the demand for reliable and ethically sourced cellular starting materials is expected to increase, shaping the future of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Cellular Starting Materials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Cellular Starting Leukopaks, Cellular Starting Cells and Tissues); Grade (Good Manufacturing Practices Grade, Research-Use Grade); End-Use (Pharmaceutical and Biotechnology Companies End-Use, Academic and Research Institutes End-Use, CMOs and CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AcceGen
  • AllCells
  • Anthony Nolan
  • ATCC (American Type Culture Collection)
  • BioIVT
  • Bio-Rad Laboratories, Inc.
  • Biospherix
  • CellGenix
  • CGT GLOBAL
  • Charles River Laboratories
  • Corning Incorporated
  • Excellos
  • Fisher Scientific
  • GE Healthcare (Cytiva)
  • Haplogen GmbH
  • HumanCells Bio
  • Lonza Group
  • Medpace
  • Merck KGaA
  • NMDP BioTherapies

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP29881

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cellular Starting Materials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for High-Quality Starting Materials Propels Cell Therapy and Biomanufacturing Expansion
    • Standardization of Cell Sources Enhances Reproducibility and Downstream Processing
    • Increased Use of iPSCs and Primary Cells Fuels Specialized Starting Material Demand
    • Focus on Cell Line Stability and Genetic Integrity Strengthens Business Case for QC-Compliant Sources
    • Growth in Personalized Medicine Drives Custom and Patient-Derived Material Usage
    • Integration of Closed Systems and Aseptic Handling Enhances Regulatory Readiness
    • Expanding Applications in Immunotherapy and Regenerative Medicine Broadens Material Requirements
    • Strategic Sourcing of Donor-Derived Cells Supports Scale-Up of Allogeneic Therapies
    • Rising Adoption of Xeno-Free and Serum-Free Media Enhances Clinical Viability
    • Advancements in Cryopreservation Techniques Improve Supply Chain Resilience
    • Collaboration Between Biobanks and Therapy Developers Accelerates Commercialization
    • Increased Transparency and Traceability Strengthen GMP Compliance Across Supply Chains
    • Automation in Cell Isolation and Expansion Technologies Supports High-Throughput Needs
    • Growth of Contract Manufacturing Spurs Demand for Consistent Starting Material Supplies
    • Emergence of Ethical and Regulatory Frameworks Promotes Responsible Sourcing Practices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cellular Starting Materials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cellular Starting Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cellular Starting Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cellular Starting Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cellular Starting Leukopaks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cellular Starting Leukopaks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cellular Starting Leukopaks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cellular Starting Cells & Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cellular Starting Cells & Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cellular Starting Cells & Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Good Manufacturing Practices Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Good Manufacturing Practices Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Good Manufacturing Practices Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Research-Use Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Research-Use Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Research-Use Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for CMOs & CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Cellular Starting Materials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Cellular Starting Materials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of World 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!